Thrombate III: payments to doctors
Payments that named Thrombate III as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $245K
- Providers
- 528
- Transactions
- 816
- Average per transaction
- $300
The per-transaction average — $300 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 528 providers the average total is $463, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Grifols USA, LLC | $157,880 | 64.5% |
| Grifols Shared Services North America, Inc. | $56,851 | 23.2% |
| Grifols, S.A. | $29,881 | 12.2% |